Our system is currently under heavy load due to increased usage. We're actively working on upgrades to improve performance. Thank you for your patience.
2006
DOI: 10.1179/016164106x116791
|View full text |Cite
|
Sign up to set email alerts
|

Autologous mesenchymal stem cells: clinical applications in amyotrophic lateral sclerosis

Abstract: Our results demonstrate that direct injection of autologous expanded MSCs into the spinal cord of ALS patients is safe, with no significant acute or late toxicity, and well tolerated. The clinical results seem to be encouraging.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

9
91
0
4

Year Published

2007
2007
2019
2019

Publication Types

Select...
8
2

Relationship

0
10

Authors

Journals

citations
Cited by 173 publications
(104 citation statements)
references
References 20 publications
9
91
0
4
Order By: Relevance
“…Intraspinal autologous MSC application was used in seven amyotrophic lateral sclerosis patients in Italy. 60 No patient manifested major adverse events such as respiratory failure or death. Minor adverse events were intercostal pain irradiation and leg sensory dysesthesia, both reversible after a mean period of 6 weeks.…”
Section: Stem Cells In Cnsmentioning
confidence: 99%
“…Intraspinal autologous MSC application was used in seven amyotrophic lateral sclerosis patients in Italy. 60 No patient manifested major adverse events such as respiratory failure or death. Minor adverse events were intercostal pain irradiation and leg sensory dysesthesia, both reversible after a mean period of 6 weeks.…”
Section: Stem Cells In Cnsmentioning
confidence: 99%
“…So far, MSCs have already been used in several clinical trials including neurological diseases and spinal injury (17,18), with results that have fallen short of any high expectations. It has been speculated that one of reasons was an insufficient knowledge of physiological behavior of MSCs.…”
mentioning
confidence: 99%
“…A low (0.3 x 10 6 MSC/kg) and a high cell dose (0.6 x 10 6 MSC/kg) product was prepared and transferred to 1 cc syringes. When translated to a clinical setting, the above doses will be comparable to the infusion of 0.1 x 10 6 /kg to 2.5 x 10 6 MSC /kg, which is similar to the range of MSC utilized or proposed in clinical studies [21,[24][25][26].…”
Section: Cell Infusionmentioning
confidence: 96%